Skip to main content

Advertisement

Table 2  KRAS  mutation frequency in the investigated subcohort (  KRAS  Wild type: 128 (63.7%),  KRAS  Mutation 73 (36.3%))

From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

    relative frequency of occurrence (%) absolute frequency of occurrence
CODON 12 mutation:    
Aspartate (G12D) c.35G>A 12,4 25
Valine (G12V) c.35G>T 6,5 13
Alanine (G12A) c.35G>C 3,4 7
Cysteine (G12C) c.34G>T 3 6
Serine (G12S) c.34G>A 3 6
Arginine (G12R) c.34G>C 0,5 1
CODON 13 mutation:    
Aspartate (G13D) c.38G>A 7,5 15